Chemoprevention of Head and Neck Squamous Cell Carcinoma (HNSCC) With Valproic Acid
Status:
Completed
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
This study evaluates the addition of valproic acid as a chemopreventive drug in head and neck
squamous cell carcinoma (HNSCC) patients that do not have signs of recurrence or residual
disease. The participants will be randomized 1:1 (valproic acid : placebo). The primary
outcome is to document histone acetylation and DNA methyltransferase expression (DNMT) in
saliva collected from participants when comparing valproic acid arm with placebo arm.